M7824, an immunotherapy candidate being developed by EMD Serono, reduced tumor size in a significant number of patients with advanced non-small cell lung cancer (NSCLC), Phase 1 data shows. It’s believed that this immunotherapy and its dual approach to fighting cancer will be a notable complement to existing immuno-oncology treatments.

Find the full press statement and further information in this article.